Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Axelar began an open-label Phase II trial comparing oral AXL1717 vs. docetaxel in about 140 patients with previously treated, locally advanced or metastatic NSCLC. Sanofi (Euronext:SAN; NYSE:SNY, Par...